Investor Relations

IR Overview

FluoroPharma Medical, Inc. (OTCQB: FPMI)

FluoroPharma Medical, Inc. (FPMI) engages in the discovery, development and commercialization of proprietary medical diagnostic imaging products. The company’s initial focus is the development of breakthrough positron emission tomography (PET) imaging agents for the efficient detection and assessment of acute and chronic forms of coronary artery disease (CAD). Other products in development include agents for detection of inflamed atherosclerotic plaque in peripheral arteries, amyloid plaque in Alzheimer’s disease and agents for detection of certain types of cancer.

Quick Links

Corporate Presentation    

Recent News


Share Statistics

Outstanding: 29,095,295
(as of August 14, 2014)

Company Information

FluoroPharma Medical, Inc.
8 Hillside Ave
Suite 207
Montclair, NJ 07042

Management Team

Thijs Spoor
Chairman of the Board, CEO & President

Boyan Goumnerov, MD
COO & Vice President Clinical Trials

Tamara Rhein
CFO

Investor Relations

Richard Moyer
Cameron Associates, Inc.
Richard@cameronassoc.com
(212) 554-5466

Transfer Agent

Vstock Transfer, LLC
77 Spruce Street
Suite 201
Cedarhurst, New York 11516
(212) 828-8436

Auditors

Wolf & Company, P.C.
99 High Street
Boston, MA 02110
(617) 933-3368